ClinicalTrials.gg
CompletedNCT04825574Updated Nov 26, 2024Results posted

Study for Patients Previously Treated in Avapritinib Clinical Trials

A Phase 4 interventional study of Avapritinib in Gastrointestinal Stromal Tumors, sponsored by Blueprint Medicines Corporation. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.

Sponsored by Blueprint Medicines Corporation (part of Sanofi) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies in Gastrointestinal Stromal Tumors with a site in France — 8 open to participants now, 15 under way, 5 of them phase 3. Gastrointestinal Stromal Tumors · France.

Enrollment
44th of 45
2 · median 94
Started
2021
with 1 other
Phase 4
5 of 48
none open now
Registered
36th of 48
by date
Lead sponsor
3 of 48
Blueprint Medicines Corporation

Among the 48 studies in Gastrointestinal Stromal Tumors with a site in France, this one is the 44th largest by enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2021, is one of 5 in phase 4, and was the 36th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

8 of the 48 studies in Gastrointestinal Stromal Tumors with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Gastrointestinal Stromal Tumors with a site in France, or all of them as a file.
02

Study summary

This is an open-label extension study to provide long term safety data for GIST patients who are deriving clinical benefit from avapritinib upon the completion of avapritinib clinical trials.

03

Conditions studied

  • Gastrointestinal Stromal Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient has confirmed or unresectable GIST as established by entry in a previous avapritinib clinical trial and has been receiving treatment with avapritinib on one of these trials.
  2. Patient continues to receive clinical benefit from avapritinib treatment, as assessed by the investigator.
  3. Patient or legal guardian, if permitted by local regulatory authorities, provides .

Exclusion criteria

Exclusion Criteria:

  1. Patient requires therapy with a concomitant medication that is a strong inhibitor or strong inducer of cytochrome P450 (CYP) 3A4
  2. Patient has a history of intracranial bleeding either prior to or during avapritinib treatment
  3. Patients who have poor organ function, defined as Adverse Events of version 5.0 Grade 3 or higher at the time of enrollment must delay start of treatment until symptoms return to Grade 2 or baseline, or the start of treatment has been approved by the Sponsor.
  4. Patients who have ongoing cognitive or mood effects Adverse Events of NCI CTCAE version 5.0 higher than Grade 1 must delay start of treatment until symptoms return to Grade 1 or baseline.
  5. Women who are unwilling, if not or surgically sterile, to abstain from sexual intercourse or employ highly effective from the time of enrollment and for at least 30 days after the last dose of avapritinib. Men who are unwilling, if not surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of first dose and for at least 90 days after the last dose of avapritinib.
  6. Women who are pregnant.
  7. Women who are breast feeding.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Patients with GIST previously enrolled in avapritinib clinical trials

    Drug: Avapritinib

Interventions

  • avapritinib tablet

    Also known as: BLU-285

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events of Special Interest (AESIs)

    AESIs for avapritinib are, regardless of grade or causality: * cognitive effects which include the following terms: memory impairment, cognitive disorder, confusional state and encephalopathy. * intracranial bleeding including haemorrhage intracranial, cerebral haemorrhage , and subdural haematoma.

    Time frame: From date of first avapritinib dose through 30 days after the last avapritinib dose (up to approximately 31 months)

  2. Number of Participants With Serious Adverse Events (SAEs)

    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: From date of first avapritinib dose through 30 days after the last avapritinib dose (up to approximately 31 months)

07

Results

Posted Nov 26, 2024

Participant flow

Participant flow — Overall Study
MilestoneAvapritinib
Started2
Received at least 1 dose of study drug2
Completed0
Not completed2
Withdrew: Commercial treatment became available1
Withdrew: Disease progression1

Outcome measures

PrimaryNumber of Participants With Adverse Events of Special Interest (AESIs)

AESIs for avapritinib are, regardless of grade or causality: * cognitive effects which include the following terms: memory impairment, cognitive disorder, confusional state and encephalopathy. * intracranial bleeding including haemorrhage intracranial, cerebral haemorrhage , and subdural haematoma.

Time frame:
From date of first avapritinib dose through 30 days after the last avapritinib dose (up to approximately 31 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESIs)
ParticipantsAvapritinib
Number of Participants With Adverse Events of Special Interest (AESIs)0
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
From date of first avapritinib dose through 30 days after the last avapritinib dose (up to approximately 31 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsAvapritinib
Number of Participants With Serious Adverse Events (SAEs)1

Adverse events

Collected over From date of first avapritinib dose through 30 days after the last avapritinib dose (up to approximately 31 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Avapritinib0/2 (0%)1/2 (50%)—
Most frequent serious events
Most frequent serious events
EventAvapritinib
Gastrointestinal haemorrhageGastrointestinal disorders1/2
ArthralgiaMusculoskeletal and connective tissue disorders1/2
Abdominal painGastrointestinal disorders1/2
VomitingGastrointestinal disorders1/2

Baseline characteristics

The Safety Population was defined as all participants who received at least one dose of avapritinib. Baseline measure data are not reported for participant privacy reasons due to low enrollment

Age, Categorical
Age, Categorical(Participants)Avapritinib
<=18 years—
Between 18 and 65 years—
>=65 years—
Sex: Female, Male
Sex: Female, Male(Participants)Avapritinib
Female—
Male—
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Avapritinib
Hispanic or Latino—
Not Hispanic or Latino—
Unknown or Not Reported—
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Avapritinib
American Indian or Alaska Native—
Asian—
Native Hawaiian or Other Pacific Islander—
Black or African American—
White—
More than one race—
Unknown or Not Reported—
08

Study locations

1 site
  • Gustave Roussy Cancer Campus Grand Paris Institut de Cancerologie Gustave-Roussy
    Villejuif, Val-de-Marne 94800, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Nov 2023, 30 months.

Results were first posted in Nov 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2021
First posted
Apr 1, 2021
StartActual
May 21, 2021
Primary completionActual
Nov 23, 2023
CompletionActual
Nov 23, 2023
Results first posted
Nov 26, 2024
Last update
Nov 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04825574
Responsible party
Sponsor
First posted
Apr 1, 2021
Start date
May 21, 2021
Primary completion
Nov 23, 2023
Completion
Nov 23, 2023
Results posted
Nov 26, 2024
Last update
Nov 26, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avapritinib

Start the discussion